The U.S. Health Resources Services Administration (HRSA) has ordered South Carolina-based VistaPharm, a manufacturer of generic and over-the-counter (OTC) drugs to repay overcharges to 340B covered entities after a HRSA audit showed the company did not offer its products at the statutory ceiling price.
HRSA’s audit of VistaPharm also found that the company had an incorrect 340B Office of Pharmacy Affairs Information System (OPAIS) record. VistaPharm’s corrective action plan is still pending, HRSA said. 340B Report reached out to the company to see if it wanted to elaborate on the findings but a spokesperson declined to comment.
The U.S. Health Resources Services Administration (HRSA) has ordered South Carolina-based VistaPharm, a manufacturer of generic and over-the-counter (OTC) drugs to repay overcharges to 340B covered entities after a HRSA audit showed the company did not offer its products at the statutory ceiling price.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.